Alex Therapeutics and Pfizer have joined forces to provide evidence-based, clinically validated and personalised digital therapies to patients.
Under the partnership, the two companies will work together on medicine, marketing, clinical validation, AI, software development and psychology, initially in Germany.
Alex is a Stockholm-based Digital Therapeutics (DTx) company, which leverages artificial intelligence (AI) to treat medical conditions through its DTx Platform.
The partnership will use Alex DTx Platform, which integrates evidence-based psychology, primarily Cognitive Behavioural Therapy (CBT) and Acceptance and Commitment Therapy (ACT) with AI.
Its DTx Platform enables personalised standalone treatments to address unmet needs among patients worldwide, said Alex Therapeutics.
Alex Therapeutics CEO John Drakenberg Renander said: “The collaboration with Pfizer enables us to combine our technology and expertise with one of the world’s leading pharmaceutical companies and gives us unique access to an attractive healthcare market.
“Pfizer’s unique experience of the needs of patients and doctors provides us with the opportunity to put our technology into the hands of those that need it the most.”
The partnership would initially focus on digital therapy for the treatment of nicotine addiction with the aid of a smartphone.
Alex developed the medical device and customised it according to the requirements of the German healthcare system, in collaboration with Pfizer Germany.
Pfizer is currently conducting a large-scale clinical trial in Germany to further authenticate the medical benefits of the medical solution.
Pfizer digital innovation lab leader Josh Raysman said: “We are working around the globe to leverage innovative digital approaches to enhance patient experiences and improve health outcomes.
“With the recent Digital Supply Act, the expertise of Pfizer’s colleagues in Germany, and the capabilities of Alex Therapeutics we have an opportunity to demonstrate the potential of patient-centric partnerships focused on transforming healthcare with digital treatments.”
Pfizer Germany country manager Aylin Tüzel said: “In our efforts to give patients access to new, innovative forms of therapy, it is our aim to fully benefit from the possibilities of digitisation.”
In January 2017, Germany and Sweden announced a comprehensive partnership that tackles societal challenges within the areas of ehealth and AI.
